Trial Profile
AXIS 2: AX200 for the Treatment of Ischemic Stroke - A Multinational, Multicenter, Randomized, Doubleblind, Placebo-Controlled Phase II Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms AXIS-2
- Sponsors SYGNIS Bioscience GmbH
- 19 Mar 2021 Results (n=259) of retrospective study assessing association of these imaging markers with functional outcome after acute ischemic stroke from patients enrolled in the AXIS-2 trial presented at the International Stroke Conference 2021
- 28 Jan 2021 Results(n=259) of post hoc, exploratory and retrospective analysis , investigating association between imaging markers of brain frailty with functional outcome after acute ischemic stroke, published in the Stroke
- 14 Apr 2012 Planned number of patients changed from 328 to 350 as reported by European Clinical Trials Database.